Meeting
2016 ASCO Annual Meeting
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
Authors
Martin J. Van Den Bent
Erasmus MC Cancer Center, Rotterdam, Netherlands
Martin J. Van Den Bent , Hui Kong Gan , Andrew B. Lassman , Priya Kumthekar , Ryan Merrell , Nicholas A. Butowski , Zarnie Lwin , Tom Mikkelsen , Louis B. Nabors , Kyriakos P. Papadopoulos , Marta Penas-Prado , John Simes , Helen Wheeler , Erica J. Gomez , Ho-Jin Lee , Lisa Roberts-Rapp , Hao Xiong , Earle E. Bain , Kyle D. Holen , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunoconjugates
Clinical Trial Registration Number
NCT01800695
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2542)
DOI
10.1200/JCO.2016.34.15_suppl.2542
Abstract #
2542
Poster Bd #
242
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy.
First Author: Sandra Silberman
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia
Poster
2019 ASCO Annual Meeting
Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.
First Author: Yoshitaka Narita
Poster
2016 ASCO Annual Meeting
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
First Author: Wolfgang Wick